SynthesisPathology oncology research : POR2019

The Effectiveness of Sorafenib over Other Targeted Agents in the Second-Line Treatment of Metastatic Renal Cell Carcinoma: a Meta-Analysis.

Hou-Feng Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.